Repligen outlines strategy to drive mid-teens revenue CAGR through 2030, targets ~30% adjusted EBITDA margin

• Repligen presented at the Wells Fargo 21st Annual Healthcare Conference, outlining strategy to outpace bioprocessing market growth.
• FY25 revenue of USD 738 million; medium-term model targets a mid-teens revenue CAGR through 2030, assuming modest M&A.
• Margin plan targets about 30% adjusted EBITDA margin, alongside a “fit for growth” transformation program.
• China strategy highlighted an OEM manufacturing agreement; China revenue rose 60% in 1H-26.
• BioLife acquisition positioned as a catalyst to expand capabilities and build on momentum in bioprocessing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Repligen Corporation published the original content used to generate this news brief on September 09, 2026, and is solely responsible for the information contained therein.